Eyenovia Begin Period Cash Flow from 2010 to 2025

EYEN Stock  USD 1.15  0.11  8.73%   
Eyenovia Begin Period Cash Flow yearly trend continues to be very stable with very little volatility. Begin Period Cash Flow is likely to drop to about 15.3 M. Begin Period Cash Flow is the amount of cash Eyenovia has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. View All Fundamentals
 
Begin Period Cash Flow  
First Reported
2016-12-31
Previous Quarter
M
Current Value
2.3 M
Quarterly Volatility
9.2 M
 
Covid
Check Eyenovia financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eyenovia's main balance sheet or income statement drivers, such as Interest Income of 661.2 K, Depreciation And Amortization of 945.7 K or Interest Expense of 2.9 M, as well as many indicators such as Price To Sales Ratio of 1.7 M, Dividend Yield of 0.0 or PTB Ratio of 1.2 K. Eyenovia financial statements analysis is a perfect complement when working with Eyenovia Valuation or Volatility modules.
  
Check out the analysis of Eyenovia Correlation against competitors.
To learn how to invest in Eyenovia Stock, please use our How to Invest in Eyenovia guide.

Latest Eyenovia's Begin Period Cash Flow Growth Pattern

Below is the plot of the Begin Period Cash Flow of Eyenovia over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Eyenovia's Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eyenovia's overall financial position and show how it may be relating to other accounts over time.
Begin Period Cash Flow10 Years Trend
Slightly volatile
   Begin Period Cash Flow   
       Timeline  

Eyenovia Begin Period Cash Flow Regression Statistics

Arithmetic Mean10,817,837
Geometric Mean5,367,306
Coefficient Of Variation100.48
Mean Deviation9,785,940
Median5,249,511
Standard Deviation10,869,650
Sample Variance118.1T
Range27M
R-Value0.84
Mean Square Error36.2T
R-Squared0.71
Significance0.000038
Slope1,929,167
Total Sum of Squares1772.2T

Eyenovia Begin Period Cash Flow History

202515.3 M
202426.3 M
202322.9 M
202227.3 M
202128.4 M
202014.2 M
201919.7 M

About Eyenovia Financial Statements

Eyenovia investors utilize fundamental indicators, such as Begin Period Cash Flow, to predict how Eyenovia Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Begin Period Cash Flow26.3 M15.3 M

Pair Trading with Eyenovia

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eyenovia position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eyenovia will appreciate offsetting losses from the drop in the long position's value.

Moving together with Eyenovia Stock

  0.68CDIOW Cardio DiagnosticsPairCorr
  0.92VINC Vincerx PharmaPairCorr
  0.72ELVN Enliven TherapeuticsPairCorr

Moving against Eyenovia Stock

  0.86AZN AstraZeneca PLC ADRPairCorr
  0.85SNY Sanofi ADRPairCorr
  0.8GILD Gilead SciencesPairCorr
  0.7LLY Eli LillyPairCorr
  0.69GOSS Gossamer BioPairCorr
The ability to find closely correlated positions to Eyenovia could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eyenovia when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eyenovia - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eyenovia to buy it.
The correlation of Eyenovia is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eyenovia moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eyenovia moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eyenovia can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Eyenovia offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eyenovia's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eyenovia Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eyenovia Stock:
Check out the analysis of Eyenovia Correlation against competitors.
To learn how to invest in Eyenovia Stock, please use our How to Invest in Eyenovia guide.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eyenovia. If investors know Eyenovia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eyenovia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(55.20)
Revenue Per Share
0.047
Quarterly Revenue Growth
0.356
Return On Assets
(0.80)
Return On Equity
(3.88)
The market value of Eyenovia is measured differently than its book value, which is the value of Eyenovia that is recorded on the company's balance sheet. Investors also form their own opinion of Eyenovia's value that differs from its market value or its book value, called intrinsic value, which is Eyenovia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eyenovia's market value can be influenced by many factors that don't directly affect Eyenovia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eyenovia's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eyenovia is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eyenovia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.